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Abstract In order to gain further insight into the functional
architecture of structurally related G protein-coupled receptors,
the ORL1 (nociceptin) and opioid receptors, we have constructed
chimeras of ORL1 and W-, N- and U-opioid receptors, and
compared their binding and functional properties with those of
the parent receptors. We find in particular that a ORL1^
U-opioid (O-K) hybrid construct has retained high affinity for
non-type-selective opiate ligands, and has acquired the ability to
bind and respond to enkephalins and W- and/or N-opioid receptor-
selective enkephalins analogs, thus behaving like a ‘universal’
opioid receptor. Most significantly however, whilst the ORL1
and U-opioid receptors display high binding preference (KD 0.1
vs. 100 nM) for their respective endogenous ligands, nociceptin
and dynorphin A, the O-K chimeric receptor binds both
nociceptin and dynorphin A, with high affinity (KD6 1 nM).
Together, these data (i) add weight to the hypothesis that the
extracellular loops of opioid receptors act as a filter for ligand
selection, and (ii) demonstrate that different domains of the
ORL1 and U-opioid receptors are involved in recognition of their
endogenous peptide ligands.
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1. Introduction
The ORL1 (opioid receptor-like 1) receptor [1^8] is the non-
opioid, G protein-coupled receptor whose primary structure is
most closely related to those of the W (MOR1), N (DOR1) and
U (KOR1) types of opioid receptor. In terms of percent ho-
mology, based on sequence alignment, the ORL1 receptor is
nearly equidistant (63^65%) to the three types of opioid re-
ceptor, amino acid conservation being prominent in the puta-
tive transmembrane domains and cytoplasmic loops. How-
ever, the ORL1 receptor possesses a common structural
feature with the U-opioid receptor, but not present in either
the W- or the N-opioid receptors, i.e. a highly acidic second
exofacial loop. On the basis of these physical characteristics,
the ORL1 receptor appears to be structurally closer to the U
than to the W and N types of opioid receptor. The endogenous
agonist of the ORL1 receptor, nociceptin [9] or orphanin FQ
[10], was recently identi¢ed in nerve tissue extracts as a highly
basic neuropeptide of 17 amino acids. Nociceptin is similar in
composition to the naturally occurring opioid heptadecapep-
tide dynorphin A, the endogenous agonist of the U-opioid
receptor. It has been suggested that nociceptin might interact
with the ORL1 receptor through the same mechanism(s) as
dynorphin A does with the U-opioid receptor [9]. In vitro, the
two peptides display high selectivity toward their respective
receptors: nociceptin binds the ORL1 receptor with 500^
1000-fold the a⁄nity it does the U-opioid receptor, while, con-
versely, dynorphin A binds the U-opioid receptor with 500^
1000-fold the a⁄nity it does the ORL1 receptor.
The dual homology of receptors and of peptide ligands
provides a unique opportunity to compare the functional ar-
chitectures of the ORL1 and opioid receptors. With this ob-
jective in mind, we have constructed ORL1^MOR1 (O-M),
-DOR1 (O-D) and -KOR1 (O-K) receptor cDNA chimeras,
and stably expressed them in CHO cells. The binding and
functional properties of the chimeric receptors have been com-
pared with those of the parent ORL1 and opioid receptors.
We ¢nd in particular that the O-K hybrid receptor not only
binds nociceptin and dynorphin A with high a⁄nities, but
also opioids lacking a⁄nity for the two wild-type receptors.
In marked contrast, the reciprocal (K-O) chimeric receptor is
inactive. These results are discussed in terms of di¡erent no-
ciceptin and dynorphin A binding domains in the parent
ORL1 and U-opioid receptors. Notwithstanding the apparent
structural similarity of the two peptide-receptor systems, the
mechanisms of peptide recognition and activation are clearly
di¡erent.
2. Materials and methods
2.1. Construction of the chimeric cDNAs
The human cDNAs encoding the ORL1 [1], MOR1 (a gift from Dr
L. Emorine), DOR1 and KOR1 (gifts from Dr B. Kie¡er) receptors,
inserted in Stratagene’s Bluescript SK plasmid, were used. The O-M,
O-D, O-K and reciprocal M-O, D-O and K-O chimeric cDNAs were
constructed at a common A£III restriction site present in the cDNA
region encoding the third transmembrane helix of the four receptors.
Since the DOR1 cDNA contains an additional A£III site, partial
digestion was used to obtain the appropriate fragment for construc-
tion of the O-D and D-O chimeras. The O-M, O-D and O-K chimeric
cDNAs encoded ORL1 residues 1^133, followed by MOR1 residues
152^400, DOR1 residues 131^372 and KOR1 residues 142^380, re-
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mide; EKC, ethylketocyclazocine; nor-BNI, nor-binaltorphimine
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spectively. The reciprocal M-O, D-O and K-O chimeric cDNAs en-
coded MOR1 residues 1^151, DOR1 residues 1^130 and KOR1 res-
idues 1^141, followed by ORL1 residues 134^370, respectively. The
cDNAs were transferred into the eukaryotic expression vector pRC/
CMV (Invitrogen). All constructs were veri¢ed by restriction endonu-
clease analysis and sequencing.
2.2. Expression of the chimeric receptors
Chinese hamster ovary cells (CHO-K1) were transfected with 5 Wg
of Qiagen-puri¢ed plasmid DNA using the calcium phosphate precip-
itation method [11]. Colonies with stable expression were selected in
culture medium containing 400 Wg/ml geneticin (Gibco BRL), on the
basis of etorphine (10 WM) inhibition of forskolin-induced accumula-
tion of cAMP, and speci¢c binding of [3H]diprenorphine and/or
[3H]nociceptin.
2.3. Membrane preparation
The transfected cells were harvested by centrifugation (2500Ug for
15 min) in ice-cold phosphate-bu¡ered saline. The pellet was homo-
genized using a Polytron homogenizer in 0.05 M Tris-HCl (pH 7.6)
and 1 mM EDTA, and the suspension was centrifuged (1000Ug for
15 min) at 4‡C in order to remove unbroken cells and nuclei. The
resulting supernatant was then centrifuged at 100 000Ug for 35 min at
4‡C. The pellet was resuspended in the 50 mM Tris, EDTA 1 mM, pH
7.6 bu¡er and used in the radioligand binding assay. Protein concen-
tration was determined according to Lowry et al. [12] with bovine
serum albumin as the standard.
2.4. Binding and competition studies
[3H]Diprenorphine (1.52 TBq/mmol, Amersham) or [3H]ethyl-
ketocyclazocine (0.67 TBq/mmol, New England Nuclear) were used
to probe the O-K and U-opioid receptor sites, and [3H]nociceptin (0.85
TBq/mmol, Amersham) to probe the O-K and ORL1 binding sites.
To minimize loss of material, particularly of nociceptin and dynor-
phin A, due to non-speci¢c adsorption, the following precautions were
taken: (i) stock solutions and intermediate dilutions of peptides were
in 0.1 mg/ml protease-free BSA (fraction V, Sigma) in polypropylene
tubes, (ii) binding and competition studies were carried out in poly-
propylene tubes in the presence of 0.1 mg/ml protease-free bovine
serum albumin (BSA), and (iii) glass ¢ber disks (Whatman GF/B)
pre-soaked in polyethyleneimine (0.33%, v:v) were used. For equilib-
rium binding studies, each incubation mixture (0.5 ml, in triplicate)
contained about 30 Wg membrane protein and [3H]diprenorphine or
[3H]nociceptin at the desired concentration (in the range 0.02^2 nM)
in 50 mM Tris-HCl, pH 7.5. Non-speci¢c binding was determined in
the presence of 1 WM unlabelled diprenorphine or nociceptin. Follow-
ing a 1 h incubation at 25‡C, unbound radioligand was removed by
rapid suction through glass ¢ber ¢lters (see above) and rinsed three
times with 4 ml 10 mM Tris-HCl bu¡er (pH 7.5). Filter-bound radio-
activity was counted in 3 ml of Beckman Ready Protein cocktail
using a Kontron MR 300 liquid scintillation counter. In the competi-
tion studies, each incubation mixture (0.5 ml, in triplicate) consisted
of 30 Wg membrane protein, [3H]diprenorphine, [3H]ethylketo-
cyclazocine or [3H]nociceptin at a ¢xed concentration of 1 nM, to-
gether with the unlabelled ligand at the desired concentration, in
50 mM Tris-HCl, pH 7.5. Total (no unlabelled ligand) and non-spe-
ci¢c (+1 WM unlabelled diprenorphine or nociceptin) binding was
determined in triplicate. Bound radioactivity was isolated and meas-
ured as described above.
2.5. Assay for intracellular cyclic AMP
Sterile hemolysis tubes were seeded with V200 000 recombinant
CHO cells in culture medium and incubated overnight at 37‡C. The
culture medium was then removed and replaced by 200 Wl of HEPES-
bu¡ered Krebs-Ringer saline (KRH: 124 mM NaCl, 5 mM KCl, 1.25
mM MgSO4, 1.5 mM CaCl2, 1.25 mM KH2PO4, 25 mM HEPES,
8 mM glucose, 0.5 mg/ml BSA; pH 7.4) containing 0.1 WM adenine
and 0.6 WCi [3H]adenine (0.85 TBq/mmol, Amersham). After 1 h at
37‡C, the cells were rinsed with 400 Wl of KRH and 180 Wl of fresh
KRH was added to each tube. Intracellular accumulation of cAMP
was initiated by addition of 20 Wl of KRH containing 100 WM for-
skolin (Sigma), 1 mM 3-isobutyl-1-methylxanthine (Sigma), 1 mM
Ro20-1724 (Biomol. Res.), and the ligand(s) to be tested at 10-fold
the desired ¢nal concentration. After exactly 10 min at 37‡C, the
reaction was stopped by addition of 20 Wl HCl 2.2 N and rapid mixing
(Vortex), and the [3H]cAMP content of each tube was determined by
selective batch elution on columns of 0.65 g alumina (activity grade 1,
type WA-1: acid, Sigma) essentially as described by Alvarez and
Daniels [13].
2.6. Unlabelled ligands
Dynorphin A and nociceptin were solid phase synthesized in the
laboratory by Dr H. Mazarguil. [Leu5]Enkephalin, [Met5]enkephalin,
DAGO and DTLET were from Bachem, etorphine and diprenorphine
from Reckitt and Colman, EKC from Sterling Winthrop, nor-BNI
and U-50488 from Research Biochemicals. Lofentanil was kindly pro-
vided by Dr. J. Leysen (Janssen Pharmaceuticals).
2.7. Analysis of the data
Non-linear regression analysis of the data was performed using
Prism version 2.0 from GraphPad Software, San Diego, CA, USA.
3. Results
In saturation binding experiments, the O-K hybrid receptor
(Fig. 1) was found to bind [3H]diprenorphine, a non-selective
opiate receptor antagonist, and [3H]ethylketocyclazocine, a
non-selective opiate, with a⁄nities comparable to those of
the U-opioid receptor (KD values at 0.1 and 0.4 nM, respec-
tively), as well as [3H]nociceptin with an a⁄nity hardly lower
(KD = 0.4 nM) than the ORL1 receptor, already indicating the
mixed ORL1 and KOR1 nature of the O-K chimera (Fig. 2).
In marked contrast, the O-M and O-D chimeric receptors,
although they bound [3H]diprenorphine with high a⁄nity
(KD values of 0.5 and 0.3 nM, respectively), failed to bind
nociceptin (KIs 10 WM). Moreover, the reciprocal M-O,
D-O and K-O hybrid receptors, whose expression in CHO
was assessed qualitatively both at the mRNA level by
Northern blotting, and at the protein level by using a poly-
clonal antibody to the ORL1 receptor (data not shown), could
not be shown to bind any of the three radioligands.
The binding properties of the ORL1, O-K hybrid and
U-opioid receptors were further investigated, in competition
experiments with various unlabelled ligands, using
[3H]nociceptin as a probe of the ORL1 receptor.
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Fig. 1. Putative secondary structure and transmembrane organiza-
tion of the ORL1(1^133)^KOR1-(142^380) (O-K) chimeric receptor.
The amino acid residues at the junction of the two receptor se-
quences are boxed. e: extracellular loop; i : intracellular loop; pm:
plasma membrane; N: amino-end (extracellular); C: carboxyl-end
(cytoplasmic).
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[3H]Diprenorphine and [3H]ethylketocyclazocine were used to
probe the U-opioid receptors, and any one of the three radio-
ligands to probe the O-K chimeric receptor. The results are
presented in Table 1. The U-opioid receptor bound a number
of ligands with high a⁄nity, particularly dynorphin A
(KI = 0.17 nM), the U-selective agonist U-50488H (KI =
3 nM) and nor-BNI (KI = 0.3 nM), a U-selective antagonist.
The U-opioid receptor showed only low a⁄nity for nociceptin
(KIW100 nM), and bound neither Met- and Leu-enkephalin,
nor DAGO and DTLET, the respective W- and N-opioid re-
ceptor-selective enkephalin analogs. Amongst the opioid lig-
ands tested, only a few displayed a measurable potency in
binding competition for [3H]nociceptin at the ORL1 receptor.
These included lofentanil (KI = 24 nM), the opioid peptide
dynorphin A (KI = 110 nM) and the non-selective opiate etor-
phine (KI = 530 nM). In particular, the ORL1 receptor did not
bind diprenorphine (KIs 10 WM), the U agonists EKC and
U-50488H, the U antagonist nor-BNI, enkephalins and enke-
phalin analogues. The O-K hybrid receptor displayed a very
di¡erent pharmacological pro¢le. Unlike the parent receptors,
the O-K receptor bound all the ligands tested with high to
moderate a⁄nities, and had therefore acquired new binding
capabilities. In addition to exhibiting high a⁄nity both for
diprenorphine and nociceptin (see above), and dynorphin A
(KIW0.1 nM), the O-K receptor recognized ligands that
the ORL1 and U-opioid receptors normally do not, particu-
larly the enkephalins and their respective W- and N-selective
analogs DAGO and DTLET. Table 1 also shows that the
hybrid receptor binding pro¢le was essentially the same,
irrespective of the probe used ([3H]diprenorphine,
[3H]ethylketocyclazocine or [3H]nociceptin), suggesting that
the ligands, although not structurally related, interact with
overlapping binding sites in the chimera.
The O-K hybrid receptor was functional, mediating inhi-
bition of forskolin-induced accumulation of cyclic AMP in in-
tact recombinant CHO cells, not only by nociceptin and dy-
norphin A but also and most noteworthy, by Met- and Leu-
enkephalin, DAGO and DTLET (Table 2). Indeed, these pep-
tides and analogs were several hundred fold more potent ago-
nists of the O-K receptor than of the ORL1 and U-opioid
receptors. Ligands exhibiting very little a⁄nity (KI values
v1 WM) did not stimulate any of the three receptors, other-
wise they showed full agonist activity, producing maximal
inhibition (approx. 80%) of forskolin-induced accumulation
of cAMP. Dynorphin A and nociceptin, while displaying ap-
preciable a⁄nity for the ORL1 and U-opioid receptor, respec-
tively, failed to stimulate these receptors. Poor correlation
between receptor binding a⁄nity and biological activity was
observed for the majority of the ligands acting at the O-K
hybrid receptor, consistent with the presence of distinct bind-
ing and transduction sites. The O-M and O-D chimeric recep-
tors were insensitive, or nearly so, to dynorphin A (ED50W0.5
and s 1 WM, respectively), and nociceptin (ED50s 10 WM)
(Table 3). They were, however, responsive to the non-selective
opiate etorphine (ED50 values of 1.3 and 0.9 nM, respec-
tively).
4. Discussion
The fact that the O-K hybrid and U-opioid receptors have
high a⁄nity for the non-selective opioid receptor ligands di-
prenorphine, etorphine and ethylketocyclazocine indicates
that the two receptors contain a similar opioid binding region.
Since there is evidence that this region lies within the receptor
bundle of transmembrane helices [14], it may be concluded
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Table 1
A⁄nity (KI, nM) of nociceptin, opioids and antagonists for the ORL1, O-K hybrid and KOR1 (U-opioid) receptors expressed in CHO cells
ORL1 OK KOR1
[3H]nociceptin [3H]diprenorphine [3H]nociceptin [3H]EKC [3H]diprenorphine
Etorphine 530 þ 40 0.56 þ 0.05 0.64 þ 0.02 0.13 þ 0.00 1.6 þ 0.2
Diprenorphine s 10 000 0.09 þ 0.01 0.15 þ 0.03 0.2 þ 0.03 0.33 þ 0.06
Nociceptin 0.13 þ 0.01 0.49 þ 0.02 0.3 þ 0.01 1.2 þ 0.1 104 þ 2
Dynorphin A 111 þ 9 0.06 þ 0.01 0.22 þ 0.01 0.4 þ 0.05 0.17 þ 0.01
U-50488 s 10 000 98 þ 8 33.5 þ 2.5 27.5 þ 2.5 3 þ 0.4
Lofentanil 724.2 þ 0.3 0.14 þ 0.01 0.16 þ 0.03 0.06 þ 0.01 5.5 þ 0.6
EKC s 10 000 1.7 þ 0.1 2.1 þ 0.2 0.15 þ 0.05 1.86 þ 0.04
Nor-BNI s 10 000 0.02 þ 0.02 0.23 þ 0.01 0.13 þ 0.01 0.34 þ 0
DAGO s 10 000 68 þ 9 19.4 þ 0.8 29.5 þ 2.5 s 1 000
DTLET s 10 000 165 þ 5 25.5 þ 0.9 50 þ 5 s 1 000
[Met5]Enkephalin s 1 000 24 þ 2 40.4 þ 1.7 6.9 þ 0.9 s 1 000
[Leu5]Enkephalin s 1 000 52 þ 6 19.9 þ 1.6 21.6 þ 3 s 1 000
KI values were calculated from the concentration (IC50) of unlabelled ligand that halves binding of the indicated radioligand in competition
experiments, using the Cheng and Prussof equation [26], KI = IC50/(1+L/KD), where L and KD are the concentration of free radioligand, and the
equilibrium dissociation constant of the radioligand, respectively. Each value is the mean þ S.E.M. of values obtained from at least three separate
experiments.
Fig. 2. Saturation equilibrium binding of [3H]diprenorphine (dip),
[3H]ethylketocyclazocine (EKC), and [3H]nociceptin (noc) in mem-
branes from CHO cells expressing the O-K hybrid receptor. Scatch-
ard transform of the data. In this particular, representative experi-
ment, KD (nM) and Bmax (pmol/mg protein) values were 0.11 and
2.3 for [3H]dip, 0.26 and 2.2 for [3H]EKC, and 0.34 and 1.9 for
[3H]noc.
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that the ORL1 transmembrane amino acid residues high-
lighted in Fig. 1, which are di¡erent in ORL1 and the
U-opioid receptors, are not directly involved in opioid recog-
nition. Most signi¢cantly, the O-K hybrid receptor displays
novel binding and functional capabilities not expressed by the
U-opioid receptor, in particular a dramatically increased abil-
ity to bind and respond to the W-selective agonists lofentanil
and DAGO, the N-selective agonist DTLET, and the enkepha-
lins, whose strong aversion for the U-opioid receptor is well
documented (see [15] for a recent review). Indeed, the O-K
hybrid receptor behaves as a non-selective, ‘universal’ opioid
receptor, i.e. an opioid receptor which has lost, to a large
extent, the ability to discriminate between type-selective
opioid receptor ligands. The likely explanation is that the
O-K hybrid receptor extracellular domain, which is di¡erent
from the U-opioid receptor extracellular domain, is less e⁄ca-
cious than the latter in preventing access of W- and N-opioid
receptor ligands to the opioid binding pocket. This is in keep-
ing with the recently proposed hypothesis that the extracellu-
lar loops play a major role in ligand selection by opioid re-
ceptors, by acting as a gate or ¢lter [16]. The U-selective
agonist U-50488H appears to be an exception to the rule since
it shows a somewhat lower a⁄nity for the O-K hybrid than
for the U-opioid receptor. This particular ligand, however,
appears to require the entire U-opioid receptor apart from
the second extracellular loop for high a⁄nity binding [17].
Replacement of the U-opioid receptor sequence (1^141) by
the corresponding ORL1 receptor sequence (1^133) in the
U-opioid receptor may therefore have removed a structural
determinant necessary for high a⁄nity binding of U-50488H.
Of further note is that the O-K chimeric receptor, unlike the
ORL1 and U-opioid receptors, binds both nociceptin and dy-
norphin A with high a⁄nity. Thus, exchange of the N-termi-
nal (1^141) sequence of the U-opioid receptor for the corre-
sponding sequence (1^133) of ORL1 has conferred on the
modi¢ed opioid receptor (the O-K chimeric receptor) the abil-
ity to bind nociceptin without impairing binding of dynorphin
A. In other words, this change has not suppressed essential
determinants for dynorphin recognition, yet has introduced
crucial elements for nociceptin recognition. The identity of
the determinants involved is di⁄cult to pinpoint at present
since the two exchanged sequences have many amino acids
in common (those in gray in Fig. 1), especially in the putative
transmembrane domains and the C-terminal half of the ¢rst
exofacial loop. However, the N-terminal domain and N-ter-
minal half of exofacial loop 1 are highly divergent, suggesting
that these sequences are not critical for dynorphin A recog-
nition by the U-opioid receptor. A similar observation has
been reported for the MOR^KOR chimeric receptor equiva-
lent of O-K [17]. Conversely, the acquired ability of the O-K
hybrid receptor to bind nociceptin with very high a⁄nity can
be accounted for by the introduction of the ORL1-speci¢c
amino acid highlighted in black in Fig. 1. These are predom-
inantly located in the putative N-terminal, ¢rst and second
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Table 2
Potency (ED50, nM) of nociceptin and opioids to inhibit forskolin-induced accumulation of cAMP via the ORL1, O-K hybrid and KOR1
(U-opioid) receptors expressed in recombinant CHO cells
ORL1 OK KOR1
Etorphine 400 þ 48 0.09 þ 0.01 4.3 þ 0.8
Nociceptin 0.84 þ 0.02 115 þ 6 s 10 000
Dynorphin A s 10 000 0.13 þ 0.02 0.5 þ 0.06
U-50488 s 10 000 460 þ 53 2.95 þ 0.04
Lofentanil 6.7 þ 0.2 0.07 þ 0.01 0.32 þ 0.02
EKC s 10 000 2.9 þ 0.1 0.63 þ 0.02
DAGO s 10 000 25 þ 3 s 10 000
DTLET s 10 000 8 þ 1 s 10 000
[Met5]Enkephalin s 1 000 6.40 þ 1 s 1 000
[Leu5]Enkephalin s 1 000 5.30 þ 0.01 s 1 000
Each value is the mean þ S.E.M. of values obtained from at least three separate experiments.
Table 3
Potency (ED50, nM) of etorphine, nociceptin, and dynorphin A to inhibit forskolin-induced accumulation of cAMP via the O-M, O-D and
O-K hybrid receptors expressed in recombinant CHO cells
Each value is the mean þ S.E.M. of values obtained from at least three separate experiments.
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transmembrane domains, and ¢rst extracellular loop. How-
ever, high a⁄nity binding of nociceptin by the O-K chimera
is also expected to be contributed by residues that are com-
mon to ORL1 and KOR1, and di¡erent in MOR1 and
DOR1, since the M-O and D-O hybrid receptors neither
bind nor respond to nociceptin. Since the three opioid recep-
tor sequences diverge most in the exofacial loops, it is likely
that these, and in particular the second (see Section 1) provide
the O-K chimera with important determinants to nociceptin
recognition.
Finally, the high a⁄nity of nociceptin for the O-K hybrid
receptor is not complemented by a high biological potency.
This is di⁄cult to explain without assuming that there are (at
least) two distinct nociceptin binding subsites on the ORL1
receptor, one (the ‘address’ site) responsible for a⁄nity and
the other (the ‘message’ site), for biological activity, as has
been shown for C5a [18] and calcitonin [19] for their recep-
tors. Accordingly, the O-K hybrid receptor lacks the ORL1
receptor ‘message’ site, but contains the opioid receptor ‘mes-
sage’ site. This indicates that these sites are not the same in
the parent receptors, and that nociceptin and opioids use dif-
ferent receptor pathways for signal transduction.
In summary, the present study has identi¢ed a non-opioid^
opioid hybrid receptor (O-K) whose properties replicate, to a
large extent, and even enhance those of the parent non-opioid
(ORL1) and opioid (KOR1) receptors. The binding and ac-
tivity pro¢les of the O-K receptor (i) lend considerable sup-
port to the hypothesis of a ligand gating function for opioid
receptor extracellular domains [16] and, most importantly, (ii)
demonstrate that nociceptin and dynorphin A bind and acti-
vate their cognate receptors in di¡erent ways, in keeping with
growing evidence that nociceptin and dynorphin A have a
di¡erent functional architecture [20^26]. The O-K chimera
is, however, not a perfect bifunctional receptor since it lacks
elements supporting full responsiveness to nociceptin. A gen-
uinely ‘universal’ receptor chimera will a¡ord invaluable as-
sistance in the identi¢cation and di¡erentiation, by site-
directed mutagenesis, of residues that are important for the
recognition and activation of the ORL1 and U-opioid recep-
tors by their endogenous peptide ligands. Obviously, the O-K
hybrid receptor is a signi¢cant step toward this goal.
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